{"success":true,"data":{"pressRelease":{"id":"166340","rtpr_id":"nGNX8DRqw0-20261012","ticker":"ARDX","exchange":"NASDAQ","all_tickers":["ARDX"],"title":"Ardelyx Presents Real-World Data at ACG 2026 Showing Reduced Healthcare Resource Utilization Following IBSRELA® Initiation in Adults with IBS-C","author":"Globe Newswire","published_at":"2026-10-12T12:01:00.126Z","article_body":"WALTHAM, Mass., Oct. 12, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq:\nARDX), a commercial-stage biopharmaceutical company focused on the development\nand commercialization of innovative medicines that meet significant unmet\nmedical needs, today announced results from a real-world analysis being\npresented at the American College of Gastroenterology (ACG) 2026 Annual\nScientific Meeting showing that gastrointestinal-related healthcare resource\nutilization (GI-HCRU) dropped significantly after adults with irritable bowel\nsyndrome with constipation (IBS-C) started IBSRELA® (tenapanor). Ardelyx will\nalso present data on how IBS-C symptom burden affects quality of life, along\nwith the design and rationale of an ongoing Phase 3 study evaluating tenapanor\nin adults with chronic idiopathic constipation (CIC).\n\n\"IBS-C can affect patients in ways that extend well beyond their symptoms,\nplacing a significant burden on daily life and quality of life, including\nthrough ongoing interactions with the healthcare system. We are encouraged by\nthese real-world findings, which show a significant reduction in GI-related\nhealthcare utilization following IBSRELA initiation,\" said Rajani Dinavahi,\nMD, Chief Medical Officer of Ardelyx. \"Together with our additional data\npresented at ACG, these findings reflect our commitment to generating evidence\nthat deepens our understanding of constipation-related disorders, helps inform\npatient care, and supports continued research into the potential role of\ntenapanor beyond IBS-C.\"\n\nThe data comes from a retrospective, observational real-world analysis of 470\npatients with IBS-C who started tenapanor at a national gastroenterology\npractice. A significant reduction in median GI-related HCRU was observed, from\n4.5 visits in the year before tenapanor initiation to 3.0 visits in the year\nfollowing initiation (3.0 [IQR: 1, 6] vs. 4.5 [IQR: 2, 9]; P<0.001).\nSignificant reductions were also seen in subgroup analyses among patients who\nhad previously tried at least one IBS-C medication, regardless of BMI or\ncomorbidity burden.\n\nPresentations at ACG 2026\n(https://www.globenewswire.com/Tracker?data=LIWRQ3P9ZPNW2zXLrgfYk0m2cclEIKNT_yLOa7EnvN8OZpC6t-KzwHlooSbr3uD3vdIAV-8dXirgSkYGslff72kFwJYpGM64KBFnyUPUH30bP83tLQRaoHUQhKRKVc_k)\ninclude:\n\n Presentation Title                                                                                                                                                          Authors                                                                                        Poster Number  Presentation Details                 \n Health Care Resource Utilization Decreases Among Patients with Constipation Predominant Irritable Bowel Syndrome Following Initiation of Tenapanor: A Real-World Analysis   Kyle Staller, Alan Fossa, Megan O’Byrne, Luisa L. Scott                                        #P3082         Poster, Oct 12, 1:00 – 2:15 PM CT    \n A Phase 3, 26-Week Randomized Controlled Study to Assess Safety and Efficacy of Tenapanor for Treatment of Chronic Idiopathic Constipation in Adults: Design and Rationale  Susan Edelstein, Yang Yang, Jocelyn M. Tabora, Kenji Kozuka, Karishma Raju, Anthony J. Lembo.  #P5352         Poster, Oct 13, 1:00 – 2:15 PM CT    \n High Symptom Severity Burden is Associated with Reduced Quality of Life in US Adults with Irritable Bowel Syndrome with Constipation                                        Megan Riehl, Taya Westfield, Alan Fossa, Zachary Babcock, Johannah Ruddy, Luisa L. Scott       #P5327         Poster, Oct 13, 1:00 – 2:15 PM CT    \n\nIn addition to the poster presentations during ACG, Ardelyx is sponsoring a\nProduct Theater titled “Expanding IBS-C Care with a First-in-Class\nTreatment,” on October 12th at 2:30 PM CT, where Dr. Aja McCutchen will lead\nan engaging clinical discussion on managing adult patients with IBS-C. The\nsession will explore the pathophysiology of IBS-C, examine patient case\nstudies, and discuss practical strategies for identifying when and how to\noptimize care for patients who may not be achieving adequate symptom relief.\n\nAbout IBSRELA® (tenapanor)\n\nIBSRELA® (tenapanor) is a locally acting inhibitor of the sodium/hydrogen\nexchanger 3 (NHE3), an antiporter expressed on the apical surface of the small\nintestine and colon that is primarily responsible for the absorption of\ndietary sodium. By inhibiting NHE3, tenapanor reduces the absorption of sodium\nfrom the small intestine and colon, retaining luminal water content,\naccelerating intestinal transit time and resulting in a softer stool\nconsistency. IBSRELA has also been shown to reduce abdominal pain by\ndecreasing visceral hypersensitivity and intestinal permeability in animal\nmodels. Please see additional full Prescribing Information\n(https://www.globenewswire.com/Tracker?data=mnjAd9wMLQBZYvWAu0EwhgygmPLATXdtKZtF33gIwgs2OwNsC3v3aZwydvs5FDjphwUyfTUix-viZEI75NOks6FhXnzTehRPfUUZYcQI7EKVItzBs7M1L8WLFgAOW88rbZuAb4YyiEF8nepr9s4PzMR2b1NFhgEdl3KNO7arlzoNq-KIUmH4oYcuJzVnvb9x).\n\nAbout Irritable Bowel Syndrome with Constipation (IBS-C)\n\nIrritable bowel syndrome with constipation (IBS-C) is a gastrointestinal\ndisorder characterized by abdominal pain and altered bowel movements,\nestimated to affect 12 million people in the U.S. People living with IBS-C may\nexperience a range of symptoms, including abdominal pain, bloating and\ninfrequent, hard or difficult-to-pass stools. IBS-C can have a significant\nimpact on daily life and is associated with impaired quality of life, reduced\nproductivity, and substantial economic burden.\n\nIMPORTANT SAFETY INFORMATION (IBSRELA)\n\n WARNING: RISK OF SERIOUS DEHYDRATION IN PEDIATRIC PATIENTS IBSRELA is contraindicated in patients less than 6 years of age; in nonclinical studies in young juvenile rats administration of tenapanor caused deaths presumed to be due to dehydration. Avoid use of IBSRELA in patients 6 years to less than 12 years of age. The safety and effectiveness of IBSRELA have not been established in patients less than 18 years of age.  \n\nCONTRAINDICATIONS\n* IBSRELA is contraindicated in patients less than 6 years of age due to the\nrisk of serious dehydration.\n* IBSRELA is contraindicated in patients with known or suspected mechanical\ngastrointestinal obstruction.\nWARNINGS AND PRECAUTIONS\nRisk of Serious Dehydration in Pediatric Patients\n* IBSRELA is contraindicated in patients below 6 years of age. The safety and\neffectiveness of IBSRELA in patients less than 18 years of age have not been\nestablished. In young juvenile rats (less than 1 week old; approximate human\nage equivalent of less than 2 years of age), decreased body weight and deaths\noccurred, presumed to be due to dehydration, following oral administration of\ntenapanor. There are no data available in older juvenile rats (human age\nequivalent 2 years to less than 12 years).\n* Avoid the use of IBSRELA in patients 6 years to less than 12 years of age.\nAlthough there are no data in older juvenile rats, given the deaths in younger\nrats and the lack of clinical safety and efficacy data in pediatric patients,\navoid the use of IBSRELA in patients 6 years to less than 12 years of age.\nDiarrhea \nDiarrhea was the most common adverse reaction in two randomized, double-blind,\nplacebo-controlled trials of IBS-C. Severe diarrhea was reported in 2.5% of\nIBSRELA-treated patients. If severe diarrhea occurs, suspend dosing and\nrehydrate patient.\n\nMOST COMMON ADVERSE REACTIONS \nThe most common adverse reactions in IBSRELA-treated patients (incidence ≥2%\nand greater than placebo) were: diarrhea (16% vs 4% placebo), abdominal\ndistension (3% vs <1%), flatulence (3% vs 1%) and dizziness (2% vs <1%).\n\nINDICATION \nIBSRELA (tenapanor) is indicated for the treatment of Irritable Bowel Syndrome\nwith Constipation (IBS-C) in adults.\n\nPlease see full Prescribing Information\n(https://www.globenewswire.com/Tracker?data=mnjAd9wMLQBZYvWAu0EwhgygmPLATXdtKZtF33gIwgupe4x-em2qVnbLfYCTJ-C-nh_Oq7sGnVkHUvYAkAC_Q-w8-ef0PpkyX1-A3UZ1YSx2FUi_lj76rRRRTwbneBOD98-4XVztuBNFySfVXMu1E9WCr-y998HTD0VGglhp2WamdStAD9CznB658GXAGrpv),\nincluding Boxed Warning, for additional risk information.\n\nAbout Ardelyx\n\nArdelyx is a commercial-stage biopharmaceutical company focused on the\ndevelopment and commercialization of innovative medicines that meet\nsignificant unmet medical needs. Ardelyx has two commercial products approved\nin the United States, IBSRELA® (tenapanor) and XPHOZAH® (tenapanor). The\ncompany’s pipeline includes the Phase 3 development of IBSRELA for chronic\nidiopathic constipation (CIC) and RDX10531, a next-generation NHE3 inhibitor\nwith potential application across multiple therapeutic areas. Ardelyx works\nwith its partners to develop and commercialize its products outside of the\nUnited States. For more information, please visit https://ardelyx.com/ and\nconnect with us on X (formerly known as Twitter)\n(https://www.globenewswire.com/Tracker?data=MsAWvmdOWGYT4xaTCovD3BLXrGegxSjHgI7c1Ef46b1G6x6n3PXFTDJ1IAYscgUpRU8vJpvS2j0U2sprHnU5f0QsMNHSrpC01Nyd0l0bpuc8I6Zkjlc-8V42Y8gQ1RCj),\nLinkedIn\n(https://www.globenewswire.com/Tracker?data=M1X3xa-xaqeDKdM3XCnwpnpsl3g-_K9vdkivFTdvd392a0kUoFhwgMb_j9eFYO5q2vN_xCjr23zbhbtsdf6zuTKr9lxAxEYhcbo_-5WpNaVslHDdNZFT18SnTh1rmemP)\nand Facebook\n(https://www.globenewswire.com/Tracker?data=BlMdvYVjfZo8rravi7ig3pkFREivjf7Gb2SnhDSyJmsalLvcIk1m4IThpBrcv_3TVObkj1B0PAFDTTdLbi6GQ6PIsAUVQ2MFGU8T0GFLfSM=).\n\nForward-Looking Statements\n\nTo the extent that statements contained in this press release are not\ndescriptions of historical facts regarding Ardelyx, they are forward-looking\nstatements reflecting the current beliefs and expectations of management made\npursuant to the safe harbor of the Private Securities Litigation Reform Act of\n1995, including Ardelyx’s current expectations regarding the anticipated\npresentations at the American College of Gastroenterology (ACG) 2026 Annual\nScientific Meeting, including the timing and content of the poster\npresentations and the Product Theater session, and continued research into the\npotential role of tenapanor in CIC. Such forward-looking statements involve\nknown and unknown risks, uncertainties and other factors that are, in some\ncases, beyond our control and that could cause actual outcomes or results to\ndiffer materially from those expressed or implied by the forward-looking\nstatements. Such risks and uncertainties include, among others, uncertainties\nassociated with the development of, regulatory process for, and\ncommercialization of drugs in the U.S. and internationally, and the risk that\nreal-world, observational, survey or other analyses may not be indicative of\nfuture results or may be interpreted differently by others. Ardelyx undertakes\nno obligation to update or revise any forward-looking statements. For a\nfurther description of the risks and uncertainties that could cause actual\nresults to differ from those expressed in these forward-looking statements, as\nwell as risks relating to Ardelyx’s business in general, please refer to\nArdelyx's Quarterly Report on Form 10-Q filed with the Securities and Exchange\nCommission on August 6, 2026, and its future current and periodic reports to\nbe filed with the Securities and Exchange Commission.\n\nInvestor Contact:\nLisa Caperelli\nSVP, Investor Relations & Corporate Communications\nlcaperelli@ardelyx.com\n\nMedia Contact:\nLindsey Manuel\nAssociate Director, Corporate Communications\nlmanuel@ardelyx.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/cee4ae6d-7a85-44bf-9c02-87e7fa934ec2)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX8DRqw0-20261012","title":"Ardelyx Presents Real-World Data at ACG 2026 Showing Reduced Healthcare Resource Utilization Following IBSRELA® Initiation in Adults with IBS-C","author":"Globe Newswire","ticker":"ARDX","created":"2026-10-12T12:01:00.126Z","tickers":["ARDX"],"exchange":"NASDAQ","article_body":"WALTHAM, Mass., Oct. 12, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq:\nARDX), a commercial-stage biopharmaceutical company focused on the development\nand commercialization of innovative medicines that meet significant unmet\nmedical needs, today announced results from a real-world analysis being\npresented at the American College of Gastroenterology (ACG) 2026 Annual\nScientific Meeting showing that gastrointestinal-related healthcare resource\nutilization (GI-HCRU) dropped significantly after adults with irritable bowel\nsyndrome with constipation (IBS-C) started IBSRELA® (tenapanor). Ardelyx will\nalso present data on how IBS-C symptom burden affects quality of life, along\nwith the design and rationale of an ongoing Phase 3 study evaluating tenapanor\nin adults with chronic idiopathic constipation (CIC).\n\n\"IBS-C can affect patients in ways that extend well beyond their symptoms,\nplacing a significant burden on daily life and quality of life, including\nthrough ongoing interactions with the healthcare system. We are encouraged by\nthese real-world findings, which show a significant reduction in GI-related\nhealthcare utilization following IBSRELA initiation,\" said Rajani Dinavahi,\nMD, Chief Medical Officer of Ardelyx. \"Together with our additional data\npresented at ACG, these findings reflect our commitment to generating evidence\nthat deepens our understanding of constipation-related disorders, helps inform\npatient care, and supports continued research into the potential role of\ntenapanor beyond IBS-C.\"\n\nThe data comes from a retrospective, observational real-world analysis of 470\npatients with IBS-C who started tenapanor at a national gastroenterology\npractice. A significant reduction in median GI-related HCRU was observed, from\n4.5 visits in the year before tenapanor initiation to 3.0 visits in the year\nfollowing initiation (3.0 [IQR: 1, 6] vs. 4.5 [IQR: 2, 9]; P<0.001).\nSignificant reductions were also seen in subgroup analyses among patients who\nhad previously tried at least one IBS-C medication, regardless of BMI or\ncomorbidity burden.\n\nPresentations at ACG 2026\n(https://www.globenewswire.com/Tracker?data=LIWRQ3P9ZPNW2zXLrgfYk0m2cclEIKNT_yLOa7EnvN8OZpC6t-KzwHlooSbr3uD3vdIAV-8dXirgSkYGslff72kFwJYpGM64KBFnyUPUH30bP83tLQRaoHUQhKRKVc_k)\ninclude:\n\n Presentation Title                                                                                                                                                          Authors                                                                                        Poster Number  Presentation Details                 \n Health Care Resource Utilization Decreases Among Patients with Constipation Predominant Irritable Bowel Syndrome Following Initiation of Tenapanor: A Real-World Analysis   Kyle Staller, Alan Fossa, Megan O’Byrne, Luisa L. Scott                                        #P3082         Poster, Oct 12, 1:00 – 2:15 PM CT    \n A Phase 3, 26-Week Randomized Controlled Study to Assess Safety and Efficacy of Tenapanor for Treatment of Chronic Idiopathic Constipation in Adults: Design and Rationale  Susan Edelstein, Yang Yang, Jocelyn M. Tabora, Kenji Kozuka, Karishma Raju, Anthony J. Lembo.  #P5352         Poster, Oct 13, 1:00 – 2:15 PM CT    \n High Symptom Severity Burden is Associated with Reduced Quality of Life in US Adults with Irritable Bowel Syndrome with Constipation                                        Megan Riehl, Taya Westfield, Alan Fossa, Zachary Babcock, Johannah Ruddy, Luisa L. Scott       #P5327         Poster, Oct 13, 1:00 – 2:15 PM CT    \n\nIn addition to the poster presentations during ACG, Ardelyx is sponsoring a\nProduct Theater titled “Expanding IBS-C Care with a First-in-Class\nTreatment,” on October 12th at 2:30 PM CT, where Dr. Aja McCutchen will lead\nan engaging clinical discussion on managing adult patients with IBS-C. The\nsession will explore the pathophysiology of IBS-C, examine patient case\nstudies, and discuss practical strategies for identifying when and how to\noptimize care for patients who may not be achieving adequate symptom relief.\n\nAbout IBSRELA® (tenapanor)\n\nIBSRELA® (tenapanor) is a locally acting inhibitor of the sodium/hydrogen\nexchanger 3 (NHE3), an antiporter expressed on the apical surface of the small\nintestine and colon that is primarily responsible for the absorption of\ndietary sodium. By inhibiting NHE3, tenapanor reduces the absorption of sodium\nfrom the small intestine and colon, retaining luminal water content,\naccelerating intestinal transit time and resulting in a softer stool\nconsistency. IBSRELA has also been shown to reduce abdominal pain by\ndecreasing visceral hypersensitivity and intestinal permeability in animal\nmodels. Please see additional full Prescribing Information\n(https://www.globenewswire.com/Tracker?data=mnjAd9wMLQBZYvWAu0EwhgygmPLATXdtKZtF33gIwgs2OwNsC3v3aZwydvs5FDjphwUyfTUix-viZEI75NOks6FhXnzTehRPfUUZYcQI7EKVItzBs7M1L8WLFgAOW88rbZuAb4YyiEF8nepr9s4PzMR2b1NFhgEdl3KNO7arlzoNq-KIUmH4oYcuJzVnvb9x).\n\nAbout Irritable Bowel Syndrome with Constipation (IBS-C)\n\nIrritable bowel syndrome with constipation (IBS-C) is a gastrointestinal\ndisorder characterized by abdominal pain and altered bowel movements,\nestimated to affect 12 million people in the U.S. People living with IBS-C may\nexperience a range of symptoms, including abdominal pain, bloating and\ninfrequent, hard or difficult-to-pass stools. IBS-C can have a significant\nimpact on daily life and is associated with impaired quality of life, reduced\nproductivity, and substantial economic burden.\n\nIMPORTANT SAFETY INFORMATION (IBSRELA)\n\n WARNING: RISK OF SERIOUS DEHYDRATION IN PEDIATRIC PATIENTS IBSRELA is contraindicated in patients less than 6 years of age; in nonclinical studies in young juvenile rats administration of tenapanor caused deaths presumed to be due to dehydration. Avoid use of IBSRELA in patients 6 years to less than 12 years of age. The safety and effectiveness of IBSRELA have not been established in patients less than 18 years of age.  \n\nCONTRAINDICATIONS\n* IBSRELA is contraindicated in patients less than 6 years of age due to the\nrisk of serious dehydration.\n* IBSRELA is contraindicated in patients with known or suspected mechanical\ngastrointestinal obstruction.\nWARNINGS AND PRECAUTIONS\nRisk of Serious Dehydration in Pediatric Patients\n* IBSRELA is contraindicated in patients below 6 years of age. The safety and\neffectiveness of IBSRELA in patients less than 18 years of age have not been\nestablished. In young juvenile rats (less than 1 week old; approximate human\nage equivalent of less than 2 years of age), decreased body weight and deaths\noccurred, presumed to be due to dehydration, following oral administration of\ntenapanor. There are no data available in older juvenile rats (human age\nequivalent 2 years to less than 12 years).\n* Avoid the use of IBSRELA in patients 6 years to less than 12 years of age.\nAlthough there are no data in older juvenile rats, given the deaths in younger\nrats and the lack of clinical safety and efficacy data in pediatric patients,\navoid the use of IBSRELA in patients 6 years to less than 12 years of age.\nDiarrhea \nDiarrhea was the most common adverse reaction in two randomized, double-blind,\nplacebo-controlled trials of IBS-C. Severe diarrhea was reported in 2.5% of\nIBSRELA-treated patients. If severe diarrhea occurs, suspend dosing and\nrehydrate patient.\n\nMOST COMMON ADVERSE REACTIONS \nThe most common adverse reactions in IBSRELA-treated patients (incidence ≥2%\nand greater than placebo) were: diarrhea (16% vs 4% placebo), abdominal\ndistension (3% vs <1%), flatulence (3% vs 1%) and dizziness (2% vs <1%).\n\nINDICATION \nIBSRELA (tenapanor) is indicated for the treatment of Irritable Bowel Syndrome\nwith Constipation (IBS-C) in adults.\n\nPlease see full Prescribing Information\n(https://www.globenewswire.com/Tracker?data=mnjAd9wMLQBZYvWAu0EwhgygmPLATXdtKZtF33gIwgupe4x-em2qVnbLfYCTJ-C-nh_Oq7sGnVkHUvYAkAC_Q-w8-ef0PpkyX1-A3UZ1YSx2FUi_lj76rRRRTwbneBOD98-4XVztuBNFySfVXMu1E9WCr-y998HTD0VGglhp2WamdStAD9CznB658GXAGrpv),\nincluding Boxed Warning, for additional risk information.\n\nAbout Ardelyx\n\nArdelyx is a commercial-stage biopharmaceutical company focused on the\ndevelopment and commercialization of innovative medicines that meet\nsignificant unmet medical needs. Ardelyx has two commercial products approved\nin the United States, IBSRELA® (tenapanor) and XPHOZAH® (tenapanor). The\ncompany’s pipeline includes the Phase 3 development of IBSRELA for chronic\nidiopathic constipation (CIC) and RDX10531, a next-generation NHE3 inhibitor\nwith potential application across multiple therapeutic areas. Ardelyx works\nwith its partners to develop and commercialize its products outside of the\nUnited States. For more information, please visit https://ardelyx.com/ and\nconnect with us on X (formerly known as Twitter)\n(https://www.globenewswire.com/Tracker?data=MsAWvmdOWGYT4xaTCovD3BLXrGegxSjHgI7c1Ef46b1G6x6n3PXFTDJ1IAYscgUpRU8vJpvS2j0U2sprHnU5f0QsMNHSrpC01Nyd0l0bpuc8I6Zkjlc-8V42Y8gQ1RCj),\nLinkedIn\n(https://www.globenewswire.com/Tracker?data=M1X3xa-xaqeDKdM3XCnwpnpsl3g-_K9vdkivFTdvd392a0kUoFhwgMb_j9eFYO5q2vN_xCjr23zbhbtsdf6zuTKr9lxAxEYhcbo_-5WpNaVslHDdNZFT18SnTh1rmemP)\nand Facebook\n(https://www.globenewswire.com/Tracker?data=BlMdvYVjfZo8rravi7ig3pkFREivjf7Gb2SnhDSyJmsalLvcIk1m4IThpBrcv_3TVObkj1B0PAFDTTdLbi6GQ6PIsAUVQ2MFGU8T0GFLfSM=).\n\nForward-Looking Statements\n\nTo the extent that statements contained in this press release are not\ndescriptions of historical facts regarding Ardelyx, they are forward-looking\nstatements reflecting the current beliefs and expectations of management made\npursuant to the safe harbor of the Private Securities Litigation Reform Act of\n1995, including Ardelyx’s current expectations regarding the anticipated\npresentations at the American College of Gastroenterology (ACG) 2026 Annual\nScientific Meeting, including the timing and content of the poster\npresentations and the Product Theater session, and continued research into the\npotential role of tenapanor in CIC. Such forward-looking statements involve\nknown and unknown risks, uncertainties and other factors that are, in some\ncases, beyond our control and that could cause actual outcomes or results to\ndiffer materially from those expressed or implied by the forward-looking\nstatements. Such risks and uncertainties include, among others, uncertainties\nassociated with the development of, regulatory process for, and\ncommercialization of drugs in the U.S. and internationally, and the risk that\nreal-world, observational, survey or other analyses may not be indicative of\nfuture results or may be interpreted differently by others. Ardelyx undertakes\nno obligation to update or revise any forward-looking statements. For a\nfurther description of the risks and uncertainties that could cause actual\nresults to differ from those expressed in these forward-looking statements, as\nwell as risks relating to Ardelyx’s business in general, please refer to\nArdelyx's Quarterly Report on Form 10-Q filed with the Securities and Exchange\nCommission on August 6, 2026, and its future current and periodic reports to\nbe filed with the Securities and Exchange Commission.\n\nInvestor Contact:\nLisa Caperelli\nSVP, Investor Relations & Corporate Communications\nlcaperelli@ardelyx.com\n\nMedia Contact:\nLindsey Manuel\nAssociate Director, Corporate Communications\nlmanuel@ardelyx.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/cee4ae6d-7a85-44bf-9c02-87e7fa934ec2)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-10-12T12:01:00.173817437Z","server_sent_at_ms":1791806460173},"received_at":"2026-10-12T12:01:00.315Z","source_url":null},"analysis":{"id":"154700","press_release_id":"166340","analysis_json":{"industry":{"label":"Pharmaceuticals, Biotechnology & Life Sciences","sector":"Health Care"},"redFlags":[],"eventType":"clinical_trial","narrative":"Ardelyx presented real-world data at ACG 2026 showing GI-related healthcare resource utilization fell significantly after adults with IBS-C started IBSRELA (tenapanor).\n\nIn a retrospective analysis of 470 patients at a national gastroenterology practice, median GI-related visits dropped from 4.5 in the year before initiation to 3.0 in the year after (P<0.001), with consistent reductions across subgroups.\n\nArdelyx also presented the design of an ongoing Phase 3 study of tenapanor in chronic idiopathic constipation, part of its effort to expand the drug beyond IBS-C.","sentiment":"bullish","agentHooks":{"shouldPost":false,"suggestedAngle":"Real-world HCRU data strengthens the IBSRELA payer/access story, but it is conference poster evidence, not a catalyst."},"keyFigures":{"drugName":"IBSRELA (tenapanor)","phaseOfTrial":"Phase 3","customDimensions":{"p_value":"P<0.001","study_patients":470,"hru_visits_after":3,"hru_visits_before":4.5,"ibs_c_us_patients":"12 million"}},"quotedText":"We are encouraged by these real-world findings, which show a significant reduction in GI-related healthcare utilization following IBSRELA initiation","namedEntities":{"people":[{"name":"Rajani Dinavahi","role":"Chief Medical Officer of Ardelyx"},{"name":"Kyle Staller","role":"study author"},{"name":"Aja McCutchen","role":"Product Theater presenter"}],"products":["IBSRELA","tenapanor","XPHOZAH","RDX10531"],"companies":[{"name":"Ardelyx, Inc.","ticker":"ARDX"},{"name":"American College of Gastroenterology","relationship":"conference host"}],"dollarAmounts":[]},"materialImpact":{"score":2,"reasoning":"Real-world poster data at a medical conference showing reduced GI healthcare utilization after IBSRELA initiation is supportive commercial evidence, but it is not new regulatory or earnings news and does not change the near-term financial picture."},"tickerRelevance":{"others":[],"primary":"ARDX"},"globalImportance":20,"audienceRelevance":25,"eventTypeSecondary":["operations_update"],"importanceComponents":{"tickerTier":"small-cap biotech","eventGravity":"conference poster / real-world data","noFinancialFigures":true,"commercialRelevance":"supports IBSRELA uptake narrative"}},"event_type":"clinical_trial","event_type_secondary":["operations_update"],"sentiment":"bullish","material_impact_score":2,"narrative":"Ardelyx presented real-world data at ACG 2026 showing GI-related healthcare resource utilization fell significantly after adults with IBS-C started IBSRELA (tenapanor).\n\nIn a retrospective analysis of 470 patients at a national gastroenterology practice, median GI-related visits dropped from 4.5 in the year before initiation to 3.0 in the year after (P<0.001), with consistent reductions across subgroups.\n\nArdelyx also presented the design of an ongoing Phase 3 study of tenapanor in chronic idiopathic constipation, part of its effort to expand the drug beyond IBS-C.","key_figures":{"drugName":"IBSRELA (tenapanor)","phaseOfTrial":"Phase 3","customDimensions":{"p_value":"P<0.001","study_patients":470,"hru_visits_after":3,"hru_visits_before":4.5,"ibs_c_us_patients":"12 million"}},"named_entities":{"people":[{"name":"Rajani Dinavahi","role":"Chief Medical Officer of Ardelyx"},{"name":"Kyle Staller","role":"study author"},{"name":"Aja McCutchen","role":"Product Theater presenter"}],"products":["IBSRELA","tenapanor","XPHOZAH","RDX10531"],"companies":[{"name":"Ardelyx, Inc.","ticker":"ARDX"},{"name":"American College of Gastroenterology","relationship":"conference host"}],"dollarAmounts":[]},"model_name":"glm-5.3-flashx","prompt_hash":"sha256:5c812bd9e28b810d","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-10-12T12:01:05.390Z","global_importance":20,"audience_relevance":25,"importance_components":{"tickerTier":"small-cap biotech","eventGravity":"conference poster / real-world data","noFinancialFigures":true,"commercialRelevance":"supports IBSRELA uptake narrative"}},"durationMs":5057,"modelName":"glm-5.3-flashx"}}